ATE490465T1 - Diagnose- und prognoseverfahren von blasenkrebs. - Google Patents

Diagnose- und prognoseverfahren von blasenkrebs.

Info

Publication number
ATE490465T1
ATE490465T1 AT06719762T AT06719762T ATE490465T1 AT E490465 T1 ATE490465 T1 AT E490465T1 AT 06719762 T AT06719762 T AT 06719762T AT 06719762 T AT06719762 T AT 06719762T AT E490465 T1 ATE490465 T1 AT E490465T1
Authority
AT
Austria
Prior art keywords
bladder cancer
diagnosis
methods
present
epithelial origin
Prior art date
Application number
AT06719762T
Other languages
English (en)
Inventor
Bruce Zetter
Adam Feldman
Scott Mcdougal
Original Assignee
Childrens Medical Center
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Gen Hospital Corp filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE490465T1 publication Critical patent/ATE490465T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06719762T 2005-01-28 2006-01-30 Diagnose- und prognoseverfahren von blasenkrebs. ATE490465T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64811005P 2005-01-28 2005-01-28
PCT/US2006/003049 WO2006081473A2 (en) 2005-01-28 2006-01-30 Methods for diagnosis and prognosis of epithelial cancers

Publications (1)

Publication Number Publication Date
ATE490465T1 true ATE490465T1 (de) 2010-12-15

Family

ID=36741098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06719762T ATE490465T1 (de) 2005-01-28 2006-01-30 Diagnose- und prognoseverfahren von blasenkrebs.

Country Status (9)

Country Link
US (7) US8685659B2 (de)
EP (1) EP1842065B1 (de)
JP (1) JP2008529008A (de)
CN (1) CN101268368A (de)
AT (1) ATE490465T1 (de)
AU (1) AU2006207954A1 (de)
CA (1) CA2595377A1 (de)
DE (1) DE602006018578D1 (de)
WO (1) WO2006081473A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100022414A1 (en) 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
EP1512970A1 (de) * 2003-09-05 2005-03-09 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Verfahren zur Bestimmung der Wirkung einer Zusammensetzung auf das Profil einer Krankheit
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
DE602006018578D1 (de) * 2005-01-28 2011-01-13 Childrens Medical Center Diagnose- und prognoseverfahren von blasenkrebs.
EP3913375A1 (de) 2006-01-11 2021-11-24 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen und verfahren zur verwendung bei der bildung und steuerung von nanoreaktoren
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
KR100767878B1 (ko) * 2006-11-07 2007-10-17 전북대학교산학협력단 간세포암 진단용 조성물, 이를 포함하는 간세포암 진단키트 및 간세포암 진단방법
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
JP2010519529A (ja) * 2007-02-23 2010-06-03 プレディクティブ バイオサイエンシーズ コーポレイション 臨床的介入を指向する診断方法
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2009017475A1 (en) * 2007-07-27 2009-02-05 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers
JP5120843B2 (ja) * 2008-06-04 2013-01-16 国立大学法人山梨大学 自己免疫性膵炎の検査方法及び検査試薬
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP3415235A1 (de) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation von mikrofluidiktröpfchen
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP3392349A1 (de) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Digitale analyse von analyten
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
AU2011261308C1 (en) * 2010-06-03 2016-02-18 Idexx Laboratories, Inc. Markers for renal disease
EP2622103B2 (de) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Sandwichassays in tröpfchen
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US20130115599A1 (en) * 2011-11-08 2013-05-09 Medical Diagnostic Laboratories, Llc Increased cip2a expression and bladder cancer in humans
EP3495817A1 (de) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molekulardiagnostischer screeningtest
EP2844768B1 (de) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digitale analyse von analyten
US10568869B2 (en) * 2012-12-11 2020-02-25 Cornell University Methods for diagnosing and treating prostate cancer
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CA3016163A1 (en) * 2016-03-02 2017-09-08 Idexx Laboratories, Inc. Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US20230314408A1 (en) * 2020-07-02 2023-10-05 Gopath Laboratories Llc Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer
CN112379093B (zh) * 2020-10-22 2023-06-16 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
ES2201077T3 (es) 1993-05-28 2004-03-16 Baylor College Of Medicine Metodo y espectrometro de masas para la desorcion e ionizacion de analitos.
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
JP2001524802A (ja) 1996-07-15 2001-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ２０ｑ１３アンプリコンからの遺伝子及びそれらの使用
JPH10262680A (ja) * 1997-03-25 1998-10-06 Kirin Brewery Co Ltd Ｒｈｏ標的タンパク質ヒトｍＤｉａおよびその遺伝子
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6642007B1 (en) * 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
US20030124543A1 (en) 1999-01-15 2003-07-03 Stuart Susan G. Breast cancer marker
US6358683B1 (en) 1999-06-03 2002-03-19 The Regents Of The University Of California Blood-based assays for breast cancer
US6939714B2 (en) * 1999-06-18 2005-09-06 Biotherapies, Inc. Epithelial cell growth inhibitors
EP1214352A2 (de) 1999-09-07 2002-06-19 Viventia Biotech Inc. Bibliotheke mit erhöhter phage display von humanen vh fragmenten und verfahren zur deren herstellung
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US20040142361A1 (en) * 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7429466B2 (en) 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
WO2002086168A1 (en) 2001-04-19 2002-10-31 Ciphergen Biosystems, Inc. Biomolecule characterization using mass spectrometry and affinity tags
US7112408B2 (en) 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
CA2457432A1 (en) 2001-08-13 2003-02-27 Jan Van Der Greef Method and system for profiling biological systems
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
US20030157579A1 (en) * 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
AU2003239152A1 (en) 2002-04-23 2003-11-10 Millipore Corporation Sample preparation of biological fluids for proteomic applications
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2007525167A (ja) 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
DE602006018578D1 (de) * 2005-01-28 2011-01-13 Childrens Medical Center Diagnose- und prognoseverfahren von blasenkrebs.
WO2009017475A1 (en) 2007-07-27 2009-02-05 Children's Medical Center Corporation Methods for diagnosis and prognosis of epithelial cancers

Also Published As

Publication number Publication date
US20140106378A1 (en) 2014-04-17
AU2006207954A1 (en) 2006-08-03
US20180188252A1 (en) 2018-07-05
WO2006081473A2 (en) 2006-08-03
WO2006081473A8 (en) 2007-08-23
WO2006081473A3 (en) 2007-01-18
US20150093767A1 (en) 2015-04-02
US20080064047A1 (en) 2008-03-13
US20090239245A1 (en) 2009-09-24
US8685659B2 (en) 2014-04-01
JP2008529008A (ja) 2008-07-31
EP1842065B1 (de) 2010-12-01
US20180120319A1 (en) 2018-05-03
CA2595377A1 (en) 2006-08-03
EP1842065A4 (de) 2008-12-31
US20170023574A1 (en) 2017-01-26
EP1842065A2 (de) 2007-10-10
DE602006018578D1 (de) 2011-01-13
CN101268368A (zh) 2008-09-17

Similar Documents

Publication Publication Date Title
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
ATE527544T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
ATE501267T1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
CY1108294T1 (el) Πρωτεϊνες καρκινικων δεικτων και οι χρησεις τους
EA201070863A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
GB2467704A (en) Methods of monitoring conditions by sequence analysis
ATE524740T1 (de) Seprase als krebsmarker
DK2073008T3 (da) Forbedrede immunoassayfremgangsmåder
WO2005100999A3 (en) Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
SG165370A1 (en) Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
BR0314155A (pt) Métodos para diagnosticar câncer cervical
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
WO2009019366A3 (fr) Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties